Cyclic alternating combination chemotherapy for small cell bronchogenic carcinoma

Area of Science:

• Oncology
• Medical Oncology
• Clinical Trials

Background:

• Small cell lung cancer (SCLC) presents a significant therapeutic challenge.
• Optimizing chemotherapy regimens is critical for improving patient outcomes in SCLC.

Purpose of the Study:

• To evaluate the efficacy of cyclic alternating combination chemotherapy in patients with small cell bronchogenic carcinoma.
• To assess the impact of adding a third non-cross-resistant drug combination on response rates and survival.

Main Methods:

• Sixty-one eligible SCLC patients received alternating chemotherapy regimens.
• Initial treatment involved cyclophosphamide, methotrexate, and CCNU (CMC), followed by vincristine, adriamycin, and procarbazine (VAP).
• A subset of patients was randomized to receive a third combination of VP-16-213 and ifosfamide, cycled every 6 weeks.

Main Results:

• The addition of VAP significantly increased complete response (CR) rates in both limited and extensive disease SCLC.
• Overall CR rates were 74% for limited disease and 36% for extensive disease after VAP addition.
• The addition of VP-16-213 and ifosfamide did not further improve CR rates or survival.
• Only patients achieving a CR survived beyond 24 months, with a 23% disease-free survival at 28 months for CR patients.

Conclusions:

• Sequential administration of non-cross-resistant chemotherapy combinations can enhance CR rates in SCLC.
• Achieving a complete response is a key determinant for long-term survival in SCLC patients treated with this approach.
• Further research may explore optimal sequencing and combinations for SCLC treatment.